Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET
Company Participants
Andrea Flynn – Head-Investor Relations
Bruce Cozadd – Chairman and Chief Executive Officer
Dan Swisher – President
Rob Iannone – Executive Vice President, Global Head-R&D
Renee Gala – Executive Vice President and Chief Financial Officer
Kim Sablich – Executive Vice President and General Manager-North America
Conference Call Participants
Ken Cacciatore – Cowen
Jessica Fye – JPMorgan
Jason Gerberry – Bank of America
Marc Goodman – SVB Leerink
Brandon Folkes – Cantor Fitzgerald
Jeff Hung – Morgan Stanley
Balaji Prasad – Barclays
Rob Palermo – Goldman Sachs
Gary Nachman – BMO Capital Markets
David Amsellem – Piper Sandler
Annabel Samimy – Stifel
Oren Livnat – H. C. Wainwright
Greg Fraser – Truist Securities
Operator
Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Jazz Pharmaceuticals First Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder, this conference call is being recorded. [Operator Instructions]
At this time, I would like to turn the conference over to Ms. Andrea Flynn. Ma'am, you may begin.
Andrea Flynn
Thank you, and good afternoon, everyone. Today, Jazz Pharmaceuticals reported its first quarter 2022 financial results. The slide presentation accompanying this webcast is available on the Investors section of our website. Investors may also refer to the press release we issued earlier today, which is also posted to our website. On the call today are Bruce Cozadd, Chairman and Chief Executive Officer; Renee Gala, Executive Vice President and Chief Financial Officer; Dan Swisher, President; and Rob Iannone, Executive Vice President, Global Head of R&D; Kim Sablich, Executive Vice President and General Manager, North America; and Phil Jochelson, Neuroscience Therapeutic Head, will join the team for Q&A.
On Slide 2, I'll remind you that today's webcast includes forward-looking statements, such as those related to our future financial and operating results, including expectations related to Vision 2025 and our guidance for 2022, growth potential and anticipated development and commercialization milestones and goals, which involve risks and uncertainties that could cause actual events, performance and results to differ materially from those contained in these forward-looking statements.
We encourage you to review the statements contained in today's press release, in our slide deck and in our latest SEC disclosure documents, which identify certain factors that may cause the company's actual events, performance and results to differ materially from those contained in the forward-looking statements made on today's webcast. We undertake no duty or obligation to update our forward-looking statements.